
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. is positioned for considerable growth due to its diverse pipeline of medical technologies, which includes established products like EsoGuard and the Veris Cancer Care Platform. The company’s current valuation is deemed attractive, reflecting a balance between inherent risks and substantial upside potential, with expectations for significant revenue growth as its products advance through commercialization, particularly in 2025 and 2026. This favorable outlook is underscored by a projected increase in the company's net present value (NPV) assessment, indicating confidence in its long-term financial performance.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million for the quarter, leading to an EPS of $(0.05), which was significantly better than the consensus estimate range of $(0.13) to $(0.25). However, the company experienced a decline in its EsoGuard test processing, registering only 2,756 tests in Q2 compared to prior quarters, indicating potential challenges in demand or market acceptance. Furthermore, the outlook is marred by multiple risk factors including liquidity concerns, regulatory hurdles, competition, and shifting investor sentiment in the biotech and medtech sectors, which could impede future growth and commercialization efforts.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares